Company and City Aim to Fight Growing Problem of MRSA - a Potentially Deadly Form of Staph Infection SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- PURE Bioscience (OTC:PURE) (BULLETIN BOARD: PURE) today announced a donation of 200 gallons of Staph Attack(TM) the silver-based hard surface disinfectant created by PURE Bioscience and distributed by Enviroguard Technologies LLC specifically for populations where resistant bacteria are becoming increasingly problematic, e.g. hospitals, prisons, schools, etc. Staph Attack carries EPA-registered claims against Methicillin-resistant Staphylococcus aureus (MRSA), while maintaining the Category IV lowest-toxicity EPA rating. (Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO) PURE Bioscience recently learned of an increasingly problematic MRSA issue, (a form of staph infection particularly difficult to treat due to its resistance to antibiotics) among San Diego's homeless and by extension with the emergency responders in San Diego working to help these individuals. In an effort to supplement current city safeguards to stop the spread of the highly contagious infection, PURE is donating 800 bottles of Staph Attack, enough to treat 72,000 square feet of hard surfaces, for use by EMT, Fire Department, and Police personnel in the city of San Diego. "We greatly appreciate a local company stepping forward to help address a serious health threat in our city," stated San Diego Fire Chief Tracy Jarman. "Anything we can do to stop the spread of MRSA by creating a cleaner environment for the individuals coming into contact with the infection on a daily basis is a great asset not only to our teams but to public health as a whole." "Staph Attack has been successful in eradicating MRSA in public and governmental areas in other cities," stated Michael L. Krall, President and CEO PURE Bioscience. "We are grateful to be able to provide this solution to our own city and first responders." PURE's CEO, Michael L. Krall will present the donation to Dr. James Dunford, San Diego City Medical Director and Rod Ballard, Deputy Chief of the San Diego Fire-Rescue Department and President of San Diego Medical Services Enterprise today, at 2pm at San Diego Fire Rescue storeroom 42 located at, 3750 Kearny Villa Rd. San Diego, California. How does it work? Silver dihydrogen citrate (SDC), the patented active ingredient in Staph Attack, is an electrolytically generated source of stabilized ionic silver. In one of the mechanisms of action, the bacteria views the molecule as a food source, and once the organism consumes it, SDC destroys the bacteria by disabling proteins and halting its metabolic and reproductive functions. SDC provides 24-hour residual protection as well. SDC, a new molecular entity, is distinguished from competitors because of its superior efficacy and reduced toxicity. PURE produces and markets ready-to-use EPA-registered disinfectant products, as well as varying strengths of SDC concentrate as an active ingredient, additive or preservative for inclusion in third party products. PURE also pursues development programs for SDC as an active pharmaceutical ingredient in a variety of pharmaceutical products. Staph Attack is currently available through its distributor, Enviroguard Technologies, LLC (http://www.enviroguardtech.net/). About PURE Bioscience PURE Bioscience (PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials and boric acid-based pesticides, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. PURE Bioscience, headquartered in El Cajon, California, (San Diego metropolitan area), was incorporated in 1992. For additional information on PURE Bioscience, visit the Company's website: http://www.purebio.com/. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Media Contact: Investor Contact: Karen Sparks, Mentus Terri MacInnis, Bibicoff & Associates, Inc. (858) 455-5500 (818) 379-8500 http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO http://photoarchive.ap.org/ DATASOURCE: PURE Bioscience CONTACT: Media, Karen Sparks of Mentus, +1-858-455-5500, ; or Investors, Terri MacInnis of Bibicoff & Associates, Inc., +1-818-379-8500, , both for PURE Bioscience Web site: http://www.enviroguardtech.net/ Web site: http://www.purebio.com/

Copyright